Hot Products
| Catalog No. | Information |
| CFN90830 | 3,3'-Di-O-methylellagic acid 4'-glucoside Reference standards. |
| CFN70332 | 3',4',5,5',6,7-Hexamethoxyflavone 5,6,7,3',4',5'-Hexamethoxyflavone(HMF) has anticancer activities, it inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle. HMF may potentiate Cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channel activities through both elevation of cAMP level and binding to CFTR protein pathways, HMF may be developed as a new drug in the therapy of CFTR-related diseases such as bronchiectasis and habitual constipation. |
| CFN90238 | 3,4,5-Tricaffeoylquinic acid 3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-ĸB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease. 3,4,5-Tricaffeoylquinic acid may attenuate the proteasome inhibitor-induced programmed cell death in PC12 cells by suppressing the activation of the mitochondrial pathway and the caspase-8- and Bid-dependent pathways, the effect be attributed to its inhibitory effect on the formation of reactive oxygen species and depletion of GSH. |
| CFN98182 | 3,4,5-Trimethoxycinnamic acid 3,4,5-Trimethoxycinnamic acid has anti-stress effect, prolonging the sleeping time in animals. 3,4,5-Trimethoxycinnamic acid may exert anti-seizure activity by acting at the GABAA/BZ receptor complex. It shows hypoxia inducible factor-2 (HIF-2) inhibitory activity with EC50 value of 60.6 uM. 3,4,5-Trimethoxycinnamic acid derivatives have a potential antinarcotic effect through acting as a 5-HT(1A) receptor agonist in mice. |
| CFN70439 | 3',4',5'-Trimethoxyflavone The 3',4',5-trimethoxyflavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome. |
| CFN70432 | 3',4',7,8-Tetramethoxyflavone 3',4',7,8-Tetramethoxyflavone has antioxidant activity. |
| CFN70376 | 3',4',7-Trihydroxyisoflavone 3',4',7-Trihydroxyisoflavone has antioxidant, estrogenic, and chemoprotective activities, it inhibits the CK-II-mediated phosphorylation of 60S acidic ribosomal P proteins in vitro. CDKs and PI3K are the primary molecular targets of 3',4',7-Trihydroxyisoflavone in the suppression of EGF-induced cell proliferation. 3',4',7-Trihydroxyisoflavone nanoparticles are characterized by improved physicochemical properties, increased water solubility, and enhanced skin penetration, and these may have potential use in the future as a topical delivery formulation for the treatment of skin diseases. |
| CFN97903 | 3',4'-Dihydroxyacetophenone 3',4'-Dihydroxyacetophenone has antimicrobial activity. |
| CFN99450 | 3,4-Dihydroxybenzaldehyde 3,4-Dihydroxybenzaldehyde, a potent tyrosinase inhibitor, has antifungal activity, it can inhibit oxidative DNA damage and apoptosis via its antioxidant activity. It inhibits the phosphotransferase activity of CKII with IC(50) of about 783 microM, it may function by inhibiting oncogenic disease, at least in part, through the inhibition of CKII activity. It inhibits the H2O2-induced apoptosis of granulosa cells, promotes estradiol secretion in granulosa cells and enhanced the mRNA expression levels of steroidogenic factor 1, a promoter of key steroidogenic enzymes. |
| CFN97568 | 3,4-Dihydroxybenzoic acid 3,4-Dihydroxybenzoic acid shows significant nematicidal, antitumor, neuroprotective, antioxidant, and antimicrobial activities. 3,4-Dihydroxybenzoic acid has protection against adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity; it also protects human keratinocytes against UVB-induced oxidative stress and apoptosis.3,4-Dihydroxybenzoic acid can prevent Abeta (25-35)-induced neuronal cell damage by interfering with the increase of [Ca(2+)](c), and then by inhibiting glutamate release, generation of ROS and caspase-3 activity. |
